Axsome Therapeutics Stock — AXSM Overview

Axsome Therapeutics (AXSM) — Stock

Lead summary

Axsome Therapeutics (ticker: AXSM) is a Nasdaq‑listed biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. This article on axsome therapeutics stock outlines the company’s market listing, historical and recent price performance, key financial metrics, commercial products and late‑stage pipeline, regulatory and clinical catalysts, analyst coverage, trading characteristics, ownership, valuation context, and material investment risks — with cited primary sources for verification.

As of June 1, 2024, according to Yahoo Finance and Axsome’s investor materials, readers will find market figures and milestone timelines cited to those sources (see References). This article is informational and not investment advice; it is intended to help readers understand the market aspects of axsome therapeutics stock and where to go for primary documents.

Company overview

Axsome Therapeutics is a clinical‑stage and commercial biopharmaceutical company that focuses on novel therapies for CNS disorders. Key high‑level facts:

• Founding and headquarters: Axsome was founded in the 2010s and is headquartered in New York City (company profile). According to the company website (accessed June 2024), management is led by CEO Herriot Tabuteau (Chief Executive Officer) who is publicly represented in investor presentations and press releases. (Source: Axsome Therapeutics corporate website, accessed June 2024.)
• Business model: Axsome pursues a clinical‑development and commercialization model typical of specialty biotechs — advancing internally developed drug candidates through clinical trials, seeking regulatory approvals, and commercializing approved products directly or via partnerships. Revenue is generated primarily through product sales of approved medicines and, where applicable, milestone and collaboration income.
• Commercial products and pipeline: The company’s marketed product(s) and investigational assets are focused on CNS indications. Key named assets historically associated with Axsome include Auvelity (AXS‑05 commercial name), Sunosi (commercial presence in certain arrangements), and investigational programs referenced in public materials as AXS‑05, AXS‑07, AXS‑12, and AXS‑14. Product sales for approved medicines provide current revenue, while the pipeline represents potential future revenue sources.

(Source: Axsome Therapeutics investor relations materials and company press releases; accessed June 2024.)

Stock identification and listing

• Ticker and exchange: axsome therapeutics stock trades under the ticker AXSM on the Nasdaq Stock Market. (Source: Nasdaq company quote page; accessed June 2024.)
• Identifiers: Primary market listing is Nasdaq; standard identifiers such as ISIN and CUSIP are published on Nasdaq and company filings (see corporate filings on company site and Nasdaq page). (Source: Nasdaq listing page and company SEC filings; accessed June 2024.)
• Shares outstanding and float: As reported in public filings and summarized by financial data providers, the company’s basic shares outstanding are disclosed in quarterly and annual reports. For example, according to company filings summarized on Morningstar and Yahoo Finance (accessed June 2024), basic shares outstanding are in the order of tens of millions of shares; float and ownership structure include a mix of institutional holders and insiders. Exact share counts and float change over time — always consult the latest 10‑Q/10‑K or data provider snapshot for the current figure. (Sources: SEC filings as presented on Axsome investor relations, Morningstar, Yahoo Finance; accessed June 2024.)

Market performance and price history

• Recent price levels and market capitalization: Market price and market capitalization for axsome therapeutics stock are variable and updated intraday by market data providers. As an example snapshot, Yahoo Finance reported AXSM market capitalization in the low billions USD range as of early June 2024; please consult a live market quote for the current figure. (Source: Yahoo Finance AXSM quote; accessed June 1, 2024.)

• Historical performance: axsome therapeutics stock has experienced multi‑year volatility typical of small‑ and mid‑cap biopharmaceutical companies. Price drivers historically include clinical trial readouts, FDA approvals or regulatory actions, quarterly revenue beats/misses, and financing events. Notable historical milestones that affected the stock typically align with major clinical or regulatory news (approved indications, major trial failures or large financings). MacroTrends and TradingView maintain multi‑year charts for AXSM to visualize these moves. (Sources: MacroTrends historical price data, TradingView charts; accessed June 2024.)

• 52‑week high/low and notable runs: The 52‑week high/low is reported by market data services and changes with market action; readers should consult Yahoo Finance or Nasdaq for the live 52‑week range. Historically, axsome therapeutics stock has had pronounced runs following positive Phase 3 results or regulatory approvals and sharp drawdowns after missed endpoints or dilutionary financings. (Source: Yahoo Finance, MacroTrends; accessed June 2024.)

Key financial metrics

• Revenue and profitability: Axsome’s reported revenue in recent quarters has been driven primarily by commercial sales of approved CNS products. According to the company’s quarterly earnings releases (accessed June 2024), revenue showed year‑over‑year trends tied to product uptake and commercial execution. Net income has typically been negative in periods where R&D investment and SG&A exceed product revenue — this is common for companies balancing commercial launch costs with pipeline investment. For precise trailing‑12‑month (TTM) revenue and EPS figures, consult Morningstar, YCharts or the company’s latest 10‑Q/10‑K. (Sources: Axsome quarterly reports and SEC filings; Morningstar summary; accessed June 2024.)

• Balance sheet highlights: The company discloses cash, marketable securities, and debt levels in each quarter. As of the most recent filings in mid‑2024, Axsome reported a cash balance intended to support operations and ongoing trials but may supplement liquidity with equity or debt raises as needed. Debt/equity has historically been low relative to cash burn for many development‑stage biotechs; however, planned or executed financings can materially change capital structure. Check the latest 10‑Q for up‑to‑date cash runway estimates and short‑term liabilities. (Sources: Company 10‑Q and investor presentations; accessed June 2024.)

• Cash flow and capital structure: Free cash flow for axsome therapeutics stock has been influenced by R&D spend, selling expenses associated with commercialization, and any one‑time items such as licensing payments or litigation costs. The company has historically funded operations via a combination of product revenue and equity offerings when necessary; material dilution events are disclosed in SEC filings and investor notices. (Sources: Company cash flow statements in SEC filings; YCharts; accessed June 2024.)

Products, pipeline and commercial drivers

• Commercial portfolio: Axsome’s commercial strategy centers on CNS products that address unmet needs in depression, narcolepsy/sleep disorders, and related conditions. Marketed products (as noted in company materials) include Auvelity (commercial form of AXS‑05 after approval for certain indications) and other products or rights that may be part of the company’s portfolio or commercialization agreements. Product sales, payer coverage, and prescription trends drive current revenue. (Source: Axsome corporate website and product press releases; accessed June 2024.)

• Clinical pipeline: Key late‑stage assets historically associated with Axsome include AXS‑05, AXS‑12, AXS‑14 and AXS‑07 (nomenclature as used in clinical disclosures). Indications pursued include major depressive disorder (MDD), narcolepsy and excessive daytime sleepiness, peripheral neuropathic pain, and other CNS indications. Late‑stage (Phase 3 or registrational) results and regulatory filings are high‑impact events that can significantly affect axsome therapeutics stock valuation. (Source: Company pipeline page and clinicaltrials.gov entries referenced in company materials; accessed June 2024.)

• How outcomes affect the stock: For pipeline‑driven biotechs like Axsome, binary clinical outcomes (positive/negative trial results) and regulatory decisions tend to produce outsized stock moves. Positive Phase 3 readouts or FDA approvals often drive material rallies, while missed endpoints or adverse safety findings typically precipitate sharp declines. Commercial performance versus consensus expectations also shifts investor sentiment and analyst forecasts.

Regulatory and clinical milestones

• Recent and pending regulatory actions: Axsome’s regulatory calendar, as disclosed in press releases and investor presentations, lists FDA approvals, supplemental NDAs (sNDAs), acceptances of filings, and key Phase 3 data readouts. For example, as of mid‑2024 the company had completed or reported results from multiple pivotal trials and had ongoing regulatory interactions for certain indications. Each acceptance or approvable action from regulatory agencies (FDA) is reported in company press releases and SEC filings. (Sources: Axsome press releases and SEC filings; accessed June 2024.)

• Timeline and significance: Upcoming readouts and advisory committee interactions (if any) are listed in investor materials. These milestones are material for axsome therapeutics stock because they affect the probability of commercial approval and future revenue streams.

Recent news and catalysts

• Summary of recent events that moved the stock:

  • Reported quarterly revenue releases and accompanying commercial commentary (e.g., prescription growth trends) have been market catalysts. Company quarterly releases and webcast transcripts describe these items. (Source: Axsome quarterly earnings releases; dates vary—see company IR page; accessed June 2024.)
  • Clinical trial announcements — initiation, interim results, or primary endpoint readouts — have been notable catalysts for AXSM. (Source: Axsome press releases and clinicaltrials.gov; accessed June 2024.)
  • Regulatory filings and FDA interactions (acceptance of NDAs/sNDAs or approvals) are high‑impact; these are announced by the company and summarized by financial media (e.g., Yahoo Finance, CNN Markets). (Sources: Axsome press releases, Yahoo Finance; accessed June 2024.)

• Upcoming events commonly monitored by investors: scheduled Phase 3/registrational trial readouts, planned regulatory submission dates or action deadlines, quarterly earnings calls, and any announced business development deals or licensing arrangements.

Analyst coverage and price targets

• Consensus view: Analyst coverage for axsome therapeutics stock is typically provided by a handful of healthcare and specialty biotech analysts tracked on services such as Morningstar, Yahoo Finance and Public.com. Coverage may include buy/hold/sell ratings and price targets. As of mid‑2024, consensus sentiment among sell‑side analysts varied, with price targets reflecting a range driven by differing assumptions about commercial uptake and approval probabilities. For current counts of ratings and the median/average price target, consult Morningstar, Yahoo Finance or Public.com (accessed June 2024). (Sources: Morningstar analyst summary, Yahoo Finance analyst page, Public.com consensus; accessed June 2024.)

• Changes in sentiment: Analyst revisions tend to follow clinical readouts and quarterly revenue performance. Positive trial outcomes often trigger upgrades and higher targets; missed endpoints or weaker‑than‑expected sales can lead to downgrades. Historical analyst commentary and research notes are summarized by data providers and in financial news coverage.

Trading data and market microstructure

• Liquidity and volume: Average daily trading volume for axsome therapeutics stock is reported by market data services (Yahoo Finance, Nasdaq). As of early June 2024, average daily volume was sizable enough to enable trade execution for retail and institutional participants, though liquidity profiles can widen around news or in periods of elevated volatility. (Source: Yahoo Finance average volume metric; accessed June 2024.)

• Volatility and beta: AXSM has historically exhibited elevated volatility relative to the broad market, consistent with biopharma peers. Beta versus the S&P 500 and realized historical volatility figures are available on TradingView, YCharts and Yahoo Finance; these indicate that small‑cap biotech equities commonly have betas >1 and frequent day‑to‑day swings. (Sources: TradingView, YCharts; accessed June 2024.)

• Options, short interest and institutional activity: An active options market can exist for AXSM; options volume and open interest are shown on standard options data pages. Short interest is disclosed bi‑monthly by exchanges and summarized on data providers — elevated short interest vs float can amplify moves on news. Institutional ownership data (filed in 13F filings and summarized by Morningstar/YCharts) highlights which institutions hold AXSM and approximate stake sizes. (Sources: Nasdaq listings on short interest, Morningstar, YCharts, Options data snapshots; accessed June 2024.)

Ownership and insider activity

• Major institutional holders: Institutional investors and mutual funds that disclose 13F holdings are typically identified in data provider summaries (Morningstar, YCharts, Yahoo Finance). As of mid‑2024, a mix of healthcare‑focused funds and generalist institutional holders were listed among major stakeholders; exact stake sizes and percentages are published in provider snapshots and 13F filings. (Sources: Morningstar institutional ownership reports, SEC 13F records; accessed June 2024.)

• Insider buying/selling: Insider transactions (executive or director buys/sells) are reported to the SEC (Forms 3, 4, 5) and summarized by data services. Patterns of insider purchases or sales can be informative for market participants; every insider trade must be reviewed in context (taxes, option exercises, routine sales). (Sources: SEC insider transaction filings; accessed June 2024.)

Valuation metrics

• Common multiples: For biopharma companies with approved products, market participants often use P/S (price‑to‑sales), EV/Revenue, and forward P/E (when positive earnings appear) alongside biotech‑specific metrics such as discounted cash flow scenarios tied to drug launch assumptions and probability‑adjusted net present value (rNPV) for pipeline assets. For many clinical‑stage biotechs, P/S or rNPV are more informative than trailing P/E because earnings may be negative. Data providers (YCharts, Morningstar, Yahoo Finance) provide current multiples for AXSM that should be checked against peers. (Sources: YCharts, Morningstar; accessed June 2024.)

• Peer comparison note: Comparing axsome therapeutics stock to biotech and CNS peers requires normalization by stage (commercial vs development), revenue scale, and pipeline risk. Traditional multiples may appear rich or inexpensive depending on growth assumptions and binary event risk.

Investment considerations and risks

• Key upside drivers:

  • Successful regulatory approvals for late‑stage programs and label expansions.
  • Strong commercial uptake and durable payer coverage for marketed products.
  • Positive Phase 3 data that de‑risks pipeline assets and expands addressable markets.
  • Strategic partnerships or licensing agreements that provide non‑dilutive funding or distribution scale.

• Key risks:

  • Clinical trial failures or safety signals in pivotal studies.
  • Regulatory setbacks or delays (e.g., FDA non‑approval or requirement for additional data).
  • Commercial execution risks, including payer access, pricing pressure, and competition in the CNS space.
  • Capital markets risk: need for additional financing can dilute existing shareholders.
  • Concentration risk: revenue dependence on a small number of products increases risk if a product underperforms.

• Suitable investor profile: axsome therapeutics stock typically fits investors comfortable with biotech sector volatility, binary clinical outcomes, and a multi‑year investment horizon for potential value realization. This article does not provide personalized investment advice.

Technical and sentiment analysis (optional)

• Technical indicators: Traders commonly cite moving averages (50‑day, 200‑day), breakout levels on volume, and relative strength indicators (RSI) when timing speculative trades in axsome therapeutics stock. Chart platforms such as TradingView show common technical setups used by retail and institutional traders. (Source: TradingView; accessed June 2024.)

• Sentiment signals: Community platforms (Stocktwits, public trading communities) can amplify trading flows; spikes in social mention volume often correlate with intraday volatility. Investors should treat social sentiment as a supplementary input rather than basis for long‑term decisions. (Source: Stocktwits community streams; accessed June 2024.)

Historical timeline of key events

• Chronological highlights (illustrative — check primary sources for exact dates):
  • Company founding and early development of CNS pipeline (foundational years; company history page).
  • First pivotal trial initiations for AXS‑05, AXS‑07 and other programs (dates per clinicaltrials.gov and company press releases).
  • FDA approval of AXS‑05 for designated indication(s) and subsequent commercial launch under the brand name Auvelity (company press release; specific approval date in press release archive).
  • Quarterly earnings reports marking first or growing product revenue (company earnings releases).
  • Major financing events or equity offerings to support clinical programs (SEC filings).
  • Subsequent Phase 3 readouts and regulatory submissions or sNDA acceptances (company press releases and SEC filings).

(Each listed event above should be cross‑checked against Axsome press releases, SEC filings, and data provider timelines for the exact date and context.)

References

Primary sources used (accessed/compiled June 2024 unless otherwise noted):

• Yahoo Finance — AXSM quote and company profile (market data, 52‑week range, analyst summary). (Accessed June 2024.)
• Axsome Therapeutics official site — company overview, pipeline pages, investor relations, press releases and SEC filings (10‑Q/10‑K). (Accessed June 2024.)
• Stocktwits — community sentiment and social discussion trends for AXSM. (Accessed June 2024.)
• CNN Markets — AXSM stock page for snapshot market data. (Accessed June 2024.)
• TradingView — interactive charts and technical ideas for AXSM. (Accessed June 2024.)
• Nasdaq company quote and listing page — ticker, trading venue, regulatory identifiers. (Accessed June 2024.)
• MacroTrends — historical price data and long‑run charts for AXSM. (Accessed June 2024.)
• Morningstar — fundamentals, analyst coverage summary and financial ratios. (Accessed June 2024.)
• Public.com — aggregated analyst consensus and forecasts for AXSM. (Accessed June 2024.)
• YCharts — financial summary, valuation multiples and operating metrics. (Accessed June 2024.)

Note: Each factual claim made in this article references primary sources listed above. For transaction‑level details and up‑to‑date figures (market cap, share count, 52‑week high/low, cash balance, etc.), consult the specific source page and the date noted next to that source.

External links

Primary pages to consult for live quotes, filings and company disclosures (no hyperlinks provided here per platform rules):

• Axsome Therapeutics official website — Investor Relations and Press Releases
• Nasdaq — AXSM company quote/listing page
• Yahoo Finance — AXSM quote and metrics
• Morningstar — Axsome Therapeutics company page
• TradingView — AXSM interactive chart
• MacroTrends — AXSM historical price data
• Stocktwits — AXSM community stream

Notes on scope and usage

This article focuses solely on the market and stock aspects of axsome therapeutics stock (AXSM). It is designed to help readers understand the company’s public market profile, financial and commercial drivers, and common catalysts that move the stock. Valuation for clinical‑stage biopharmaceutical firms like Axsome is event‑driven and carries higher binary risk versus diversified industrial stocks; readers should consult primary documents, audited financial statements and SEC filings for investment decisions.

Further research tips and next steps

• For live prices and real‑time market data, consult the market quote pages listed in the External Links section.
• For precise share counts, cash balances, and recent insider transactions, read the latest 10‑Q or 10‑K and recent Forms 3/4/5 filed with the SEC.
• To trade AXSM or to custody and manage crypto‑assets in parallel workflows, consider using Bitget’s trading platform and Bitget Wallet for secure custody (platform recommendation). Always verify regulatory and account requirements before trading.

Explore more: refer to Axsome’s most recent investor presentation and audited financial statements to reconcile metrics cited here and to build your own timelines tied to regulatory milestones.